Allogene Therapeutics Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Allogene Therapeutics stock.
View analyst ratings for Allogene Therapeutics or view top-rated stocks.

Wall Street analysts have given Allogene Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Allogene Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Allogene Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Allogene Therapeutics.

Allogene Therapeutics, Inc. (NASDAQ:ALLO) released its quarterly earnings results on Tuesday, May, 4th. The company reported ($0.25) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.46) by $0.21. The business had revenue of $38.35 million for the quarter, compared to analysts' expectations of $24.50 million.
View Allogene Therapeutics' earnings history.

Allogene Therapeutics' stock was trading at $25.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ALLO shares have decreased by 1.4% and is now trading at $24.69.
View which stocks have been most impacted by COVID-19.

11 brokerages have issued 12-month target prices for Allogene Therapeutics' stock. Their forecasts range from $41.00 to $55.00. On average, they expect Allogene Therapeutics' share price to reach $45.14 in the next twelve months. This suggests a possible upside of 82.8% from the stock's current price.
View analysts' price targets for Allogene Therapeutics or view top-rated stocks among Wall Street analysts.

2 employees have rated Allogene Therapeutics CEO David Chang on Glassdoor.com. David Chang has an approval rating of 100% among Allogene Therapeutics' employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Allogene Therapeutics include Novavax (NVAX), Repligen (RGEN), QIAGEN (QGEN), CRISPR Therapeutics (CRSP), Neurocrine Biosciences (NBIX), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Acceleron Pharma (XLRN), Exelixis (EXEL), Halozyme Therapeutics (HALO), Vir Biotechnology (VIR), Adaptive Biotechnologies (ADPT), Twist Bioscience (TWST), Recursion Pharmaceuticals (RXRX) and Beam Therapeutics (BEAM).
View all of ALLO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

(ALLO) raised $272 million in an IPO on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies served as the underwriters for the IPO.

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

Allogene Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Capital International Investors (4.66%), BlackRock Inc. (4.43%), Price T Rowe Associates Inc. MD (2.44%), Alliancebernstein L.P. (1.80%), JPMorgan Chase & Co. (1.68%) and Primecap Management Co. CA (0.92%). Company insiders that own Allogene Therapeutics stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, Owen N Witte, Rafael Amado and Veer Bhavnagri.
View institutional ownership trends for Allogene Therapeutics.

ALLO stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Morgan Stanley, Millennium Management LLC, Regents of The University of California, BlackRock Inc., Goldman Sachs Group Inc., Price T Rowe Associates Inc. MD, and Cubist Systematic Strategies LLC. Company insiders that have sold Allogene Therapeutics company stock in the last year include Alison Moore, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, Owen N Witte, Rafael Amado, and Veer Bhavnagri.
View insider buying and selling activity for Allogene Therapeutics or view top insider-selling stocks.

ALLO stock was acquired by a variety of institutional investors in the last quarter, including Compagnie Lombard Odier SCmA, JPMorgan Chase & Co., Pier Capital LLC, Woodline Partners LP, Citigroup Inc., UBS Group AG, Geode Capital Management LLC, and Ergoteles LLC.
View insider buying and selling activity for Allogene Therapeutics or or view top insider-buying stocks.

Shares of ALLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALLO stock can currently be purchased for approximately $24.69.

Allogene Therapeutics has a market capitalization of $3.49 billion. The company earns $-250,220,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis.

Allogene Therapeutics employs 276 workers across the globe.

The official website for Allogene Therapeutics is www.allogene.com.

Allogene Therapeutics is headquartered at 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080.

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-457-2700 or via email at [email protected]